Nascent Biotech IncOOTC NBIO Stock Report

Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. The company is headquartered in North Palm Beach, Florida. The company went IPO on 2012-06-06. The firm focusses on biologic drug candidates that are undergoing initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The company is developing its primary asset, Pritumumab, for the treatment of brain cancer and pancreatic cancer. The company is exploring Pritumumab in its use against viruses. Its drug candidate, Pritumumab is also used for the treatment of epithelial cancers, which include lung, breast, and colon. Its initial focus is on the development of Pritumumab as an intravenous treatment of patients with various types of brain cancer, prominently gliomas, and malignant astrocytoma. Its MultiPharm is a platform technology that have additive and synergistic effects not only for cancer therapy but also diabetes, autoimmunity, and transplantation.